1 Min Read
Sept 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:
* SIGNS A LICENSE OPTION AGREEMENT WITH INSERM TO DEVELOP A NEW CANCER IMMUNOTHERAPY TARGETING MYELOID CELLS Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.